Works matching DE "CANAGLIFLOZIN"

Results: 689

Role of canagliflozin in ameliorating isoprenaline induced cardiomyocyte oxidative stress via the heme oxygenase-1 mediated pathway.

Published in:

Biotechnic & Histochemistry, 2023, v. 98, n. 8, p. 593, doi. 10.1080/10520295.2023.2262390

By:

Ahmed, Ahmed;
Abdel-Rahman, Dina;
Hantash, Ehab M.

Publication type:

Article

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.

Published in:

European Journal of Clinical Pharmacology, 2015, v. 71, n. 11, p. 1325, doi. 10.1007/s00228-015-1923-y

By:

Yang, Ting;
Lu, Min;
Ma, Lingyue;
Zhou, Ying;
Cui, Yimin

Publication type:

Article

Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.

Published in:

Biochemical Journal, 2022, v. 479, n. 3, p. 425, doi. 10.1042/BCJ20210700

By:

Hiroko Otsuka;
Hisashi Yokomizo;
Shintaro Nakamura;
Yoshihiro Izumi;
Masatomo Takahashi;
Sachiko Obara;
Motonao Nakao;
Yosuke Ikeda;
Naoichi Sato;
Ryuichi Sakamoto;
Yasutaka Miyachi;
Takashi Miyazawa;
Takeshi Bamba;
Yoshihiro Ogawa

Publication type:

Article

The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice.

Published in:

Biochemical Journal, 2020, v. 477, n. 12, p. 2347, doi. 10.1042/BCJ20200278

By:

Day, Emily A.;
Ford, Rebecca J.;
Lu, Jessie H.;
Lu, Rachel;
Lundenberg, Lucie;
Desjardins, Eric M.;
Green, Alex E.;
Lally, James S. V.;
Schertzer, Jonathan D.;
Steinberg, Gregory R.

Publication type:

Article

Canagliflozin Alleviates Atherosclerosis Progression through Inflammation, Oxidative Stress, and Autophagy in Western Diet-fed ApoE<sup>−/−</sup> Mice.

Published in:

Cardiovascular Innovations & Applications (CVIA), 2024, v. 9, p. 1, doi. 10.15212/CVIA.2023.0093

By:

Zuo, Qingjuan;
He, Lili;
Ma, Sai;
Zhang, Guorui;
Zhai, Jianlong;
Wang, Zhongli;
Zhang, Tingting;
Wang, Yan;
Guo, Yifang

Publication type:

Article

Canagliflozin Regulates Ferroptosis, Potentially via Activating AMPK/PGC-1α/Nrf2 Signaling in HFpEF Rats.

Published in:

Cardiovascular Innovations & Applications (CVIA), 2022, v. 7, n. 1, p. 1, doi. 10.15212/CVIA.2022.0024

By:

Sai Ma;
Lili He;
Qingjuan Zuo;
Guorui Zhang;
Yifang Guo

Publication type:

Article

Rhabdomyolysis and Sodium-Glucose–Linked Transport Inhibitors in Patients Taking Statins.

Published in:

JAMA Network Open, 2024, v. 7, n. 11, p. e2446641, doi. 10.1001/jamanetworkopen.2024.46641

By:

Harel, Ziv;
Jeyakumar, Nivethika;
Smith, Graham;
Ray, Joel G.;
Clemens, Kristin K.;
Juurlink, David N.

Publication type:

Article

Development and validation of HPTLC method for simultaneous estimation of canagliflozin and metformin hydrochloride in bulk and tablet dosage form.

Published in:

SA Pharmaceutical Journal Incorporating Pharmacy Management, 2017, v. 84, n. 6, p. 65

By:

R. P., Bhole;
J. S., Gandhi;
S. B., Wankhede

Publication type:

Article

Systematic Screening Study for the Selection of Proper Stabilizers to Produce Physically Stable Canagliflozin Nanosuspension by Wet Milling Method.

Published in:

Bioengineering (Basel), 2023, v. 10, n. 8, p. 927, doi. 10.3390/bioengineering10080927

By:

Pirincci Tok, Yagmur;
Mesut, Burcu;
Güngör, Sevgi;
Sarıkaya, Ali Osman;
Aldeniz, Emre Erol;
Dude, Udaya;
Özsoy, Yıldız

Publication type:

Article

Does the Availability of DPP-4 Inhibitors Affect the Glycemic Control in Patients with Type 2 Diabetes Mellitus?

Published in:

Jordan Medical Journal, 2020, v. 54, n. 1, p. 17

By:

Momani, Munther Suleiman;
Al Rawashdeh, Athar Menawer

Publication type:

Article

Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy‐arrhythmia burden in patients with cardiac implantable electronic devices.

Published in:

Journal of Cardiovascular Electrophysiology, 2023, v. 34, n. 8, p. 1595, doi. 10.1111/jce.15996

By:

Younis, Arwa;
Arous, Tania;
Klempfner, Robert;
Kharsa, Adnan;
McNitt, Scott;
Schleede, Susan;
Polonski, Bronislava;
Abdallah, Zeinab;
Buttar, Ruppinder;
Bodurian, Christopher;
Tabaja, Chadi;
Yavin, Hagai D.;
Shamroz, Farooq;
Wazni, Oussama M.;
Wittlin, Steven D.;
Aktas, Mehmet;
Goldenberg, Ilan

Publication type:

Article

Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice.

Published in:

Korean Journal of Physiology & Pharmacology, 2023, v. 27, n. 3, p. 221, doi. 10.4196/kjpp.2023.27.3.221

By:

Qian Zhu;
Qu Zhou;
Xiao-li Luo;
Xu-jie Zhang;
San-yu Li

Publication type:

Article

The combination of canagliflozin and omega-3 fatty acid ameliorates insulin resistance and cardiac biomarkers via modulation of inflammatory cytokines in type 2 diabetic rats.

Published in:

Korean Journal of Physiology & Pharmacology, 2018, v. 22, n. 5, p. 493, doi. 10.4196/kjpp.2018.22.5.493

By:

Safhi, Mohammed Mohsen;
Anwer, Tarique;
Khan, Gyas;
Siddiqui, Rahimullah;
Sivakumar, Sivagurunathan Moni;
Alam, Mohammad Firoz

Publication type:

Article

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.

Published in:

Journal of Diabetes Research, 2020, p. 1, doi. 10.1155/2020/4861681

By:

Fushimi, Yoshiro;
Obata, Atsushi;
Sanada, Junpei;
Iwamoto, Yuichiro;
Mashiko, Akiko;
Horiya, Megumi;
Mizoguchi-Tomita, Akiko;
Nishioka, Momoyo;
Kan, Yuki;
Kinoshita, Tomoe;
Okauchi, Seizo;
Hirukawa, Hidenori;
Kohara, Kenji;
Tatsumi, Fuminori;
Shimoda, Masashi;
Nakanishi, Shuhei;
Mune, Tomoatsu;
Kaku, Kohei;
Kaneto, Hideaki

Publication type:

Article

Use of Sodium-Glucose Cotransporter-2 Inhibitor for Diabetes Management in Patients Following Kidney Transplantation.

Published in:

Journal of Pharmacy Technology, 2023, v. 39, n. 3, p. 147, doi. 10.1177/87551225231169620

By:

Crannage, Erica F.;
Nguyen, Katherine L.;
Ellebrecht, Morgan D.;
Challen, Laura M.;
Crannage, Andrew J.

Publication type:

Article

Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.

Published in:

Journal of Pharmacy Technology, 2018, v. 34, n. 4, p. 144, doi. 10.1177/8755122518760984

By:

Mohammad, Hannah;
Borja-Hart, Nancy

Publication type:

Article

Metformin regulation of progesterone receptor isoform-B expression in human endometrial cancer cells is glucose-dependent.

Published in:

Oncology Letters, 2020, v. 20, n. 5, p. 1, doi. 10.3892/ol.2020.12112

By:

SAGUYOD, SOFIA JADE U.;
ALHALLAK, IAD;
SIMMEN, ROSALIA C. M.;
VELARDE, MICHAEL C.

Publication type:

Article

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians.

Published in:

Metabolites (2218-1989), 2021, v. 11, n. 11, p. 794, doi. 10.3390/metabo11110794

By:

Afzal, Muhammad;
Al-Abbasi, Fahad A.;
Nadeem, Muhammad Shahid;
Alshehri, Sultan;
Ghoneim, Mohammed M.;
Imam, Syed Sarim;
Almalki, Waleed Hassan;
Kazmi, Imran

Publication type:

Article

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.

Published in:

Life (2075-1729), 2023, v. 13, n. 4, p. 1012, doi. 10.3390/life13041012

By:

Haddad, Fatma;
Dokmak, Ghadeer;
Bader, Maryam;
Karaman, Rafik

Publication type:

Article

Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.

Published in:

Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383

By:

Buckley, SophieAnne;
Subramaniam, Yuvanaa;
Mallik, Ritwika;
Mukuba, Dorcas;
Casabar, Mahalia;
Ali, Omer;
Byrne, Connor;
Chowdhury, Tahseen A.

Publication type:

Article

Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol.

Published in:

Diabetic Medicine, 2024, v. 41, n. 6, p. 1, doi. 10.1111/dme.15320

By:

Lobato, Carolina B.;
Winding, Clara Tornoe;
Bojsen‐Møller, Kirstine N.;
Martinussen, Christoffer;
Veedfald, Simon;
Holst, Jens J.;
Madsbad, Sten;
Jørgensen, Nils Bruun;
Dirksen, Carsten

Publication type:

Article

The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.

Published in:

Diabetic Medicine, 2024, v. 41, n. 5, p. 1, doi. 10.1111/dme.15271

By:

VanDerStad, Lindsey R.;
Wyatt, Emily C.;
Vaughan, Roger A.

Publication type:

Article

Poster abstracts.

Published in:: Diabetic Medicine, 2024, v. 41, p. 1, doi. 10.1111/dme.15296
Publication type:: Article

Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.

Published in:

Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14769

By:

Karalliedde, Janaka;
Winocour, Peter;
Chowdhury, Tahseen A.;
De, Parijat;
Frankel, Andrew H.;
Montero, Rosa M.;
Pokrajac, Ana;
Banerjee, Debasish;
Dasgupta, Indranil;
Fogarty, Damian;
Sharif, Adnan;
Wahba, Mona;
Mark, Patrick B.;
Zac‐Varghese, Sagen;
Patel, Dipesh C.;
Bain, Stephen C.

Publication type:

Article

Basic and clinical science posters: Vascular and endothelial function.

Published in:: Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.22_14556
Publication type:: Article

Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.

Published in:

Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262

By:

Rajani, A.;
Sahay, M.;
Bhattacharyya, A.;
Amar, A.

Publication type:

Article

SGLT2 inhibitors in Type 1 diabetes: is this the future?

Published in:

Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791

By:

Herring, R.;
Russell‐Jones, D. L.

Publication type:

Article

Unmasking and aggravation of polycythemia vera by canagliflozin.

Published in:

Diabetic Medicine, 2018, v. 35, n. 11, p. 1613, doi. 10.1111/dme.13706

By:

Das, L.;
Bhansali, A.;
Walia, R.

Publication type:

Article

Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.

Published in:

Diabetic Medicine, 2016, v. 33, n. 12, p. 1744, doi. 10.1111/dme.13033

By:

Matthews, D. R.;
Zinman, B.;
Tong, C.;
Meininger, G.;
Polidori, D.

Publication type:

Article

Short-Term Efficacy and Tolerability of Paroxetine Versus Placebo for Panic Disorder: A Meta-Analysis of Randomized Controlled Trials.

Published in:

Frontiers in Pharmacology, 2020, p. 1, doi. 10.3389/fphar.2020.00275

By:

Zhang, Beilin;
Wang, Chao;
Cui, Lexiang;
Gao, Jiguo;
Wang, Chenglin;
Tan, Xiangyu;
Fang, Shaokuan

Publication type:

Article

real-world study on SGLT2 inhibitors and diabetic kidney disease progression.

Published in:

Clinical Kidney Journal, 2022, v. 15, n. 7, p. 1403, doi. 10.1093/ckj/sfac044

By:

Liu, Allen Yan Lun;
Low, Serena;
Yeoh, Ester;
Lim, Eng Kuang;
Renaud, Claude Jeffrey;
Teoh, Selene Tse Yen;
Tan, Grace Feng Ling;
Chai, Chung Cheen;
Liu, Bo;
Subramaniam, Tavintharan;
Sum, Chee Fang;
Lim, Su Chi

Publication type:

Article

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.

Published in:

Clinical Kidney Journal, 2021, v. 14, n. 5, p. 1396, doi. 10.1093/ckj/sfaa133

By:

Weir, Matthew R;
Slee, April;
Sun, Tao;
Balis, Dainius;
Oh, Richard;
Zeeuw, Dick de;
Perkovic, Vlado

Publication type:

Article

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

Published in:

Clinical Kidney Journal, 2019, v. 12, n. 3, p. 313, doi. 10.1093/ckj/sfz070

By:

Fernandez-Fernandez, Beatriz;
Fernandez-Prado, Raul;
Górriz, Jose Luis;
Martinez-Castelao, Alberto;
Navarro-González, Juan F;
Porrini, Esteban;
Soler, María José;
Ortiz, Alberto

Publication type:

Article

Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.

Published in:

2018

By:

Seko, Yuya;
Sumida, Yoshio;
Sasaki, Kazuyo;
Itoh, Yoshito;
Iijima, Hiroaki;
Hashimoto, Toshio;
Ishii, Shinichi;
Inagaki, Nobuya

Publication type:

journal article

Corrigendum to "A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes".

Published in:

Case Reports in Endocrinology, 2021, p. 1, doi. 10.1155/2021/7320217

By:

Hassani-Ardakani, Kimya;
Lipman, Mark L.;
Laporta, Denny;
Yu, Oriana Hoi Yun

Publication type:

Article

A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes.

Published in:

Case Reports in Endocrinology, 2019, p. 1, doi. 10.1155/2019/8639629

By:

Hassani-Ardakania, Kimya;
Lipman, Mark L.;
Laporta, Denny;
Yu, Oriana Hoi Yun

Publication type:

Article

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.

Published in:

Drugs, 2019, v. 79, n. 7, p. 733, doi. 10.1007/s40265-019-01086-0

By:

Ceriello, Antonio;
De Nigris, Valeria;
Iijima, Hiroaki;
Matsui, Takahiro;
Gouda, Maki

Publication type:

Article

Canagliflozin: A Review in Type 2 Diabetes.

Published in:

Drugs, 2017, v. 77, n. 14, p. 1577, doi. 10.1007/s40265-017-0801-6

By:

Scheen, André;
Deeks, Emma

Publication type:

Article

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.

Published in:

Frontiers in Endocrinology, 2021, v. 12, p. 1, doi. 10.3389/fendo.2021.645617

By:

Meier, Juris J.

Publication type:

Article

Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.

Published in:

Frontiers in Endocrinology, 2021, v. 11, p. N.PAG, doi. 10.3389/fendo.2021.619586

By:

Li, Daobo;
Liu, Yingying;
Hidru, Tesfaldet Habtemariam;
Yang, Xiaolei;
Wang, Yunsong;
Chen, Cheng;
Li, Ka Hou Christien;
Tang, Yuqi;
Wei, Yushan;
Tse, Gary;
Xia, Yunlong

Publication type:

Article

Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Published in:

Frontiers in Endocrinology, 2021, v. 11, p. N.PAG, doi. 10.3389/fendo.2020.604250

By:

Zhang, Ailing;
Luo, Xufei;
Meng, Haiyang;
Kang, Jian;
Qin, Guijun;
Chen, Yaolong;
Zhang, Xiaojian

Publication type:

Article

Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure.

Published in:

2024

By:

Masamune Miyazaki;
Masanobu Nakano;
Hisako Takahashi;
Yoshihiro Isaka;
Yoshikazu Hiura

Publication type:

Case Study

A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.

Published in:

American Journal of Case Reports, 2020, v. 21, p. 1, doi. 10.12659/AJCR.920115

By:

Elbeddini, Ali;
Gallinger, Jodi;
Davey, Michelle;
Brassard, Stephane;
Gazarin, Mohammed;
Plourde, Frida;
Aly, Ahmed

Publication type:

Article

새로운 당뇨병 치료제.

Published in:

Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi, 2017, v. 60, n. 12, p. 992, doi. 10.5124/jkma.2017.60.12.992

By:

김 두 만

Publication type:

Article

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.

Published in:

International Journal of Emergency Medicine, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s12245-020-0261-8

By:

Fukuda, Masafumi;
Nabeta, Masakazu;
Muta, Takanori;
Fukami, Kei;
Takasu, Osamu

Publication type:

Article

Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes.

Published in:

Vascular Medicine, 2021, v. 26, n. 2, p. 131, doi. 10.1177/1358863X20961153

By:

Nalugo, Margaret;
Harroun, Nikolai;
Li, Chenglong;
Belaygorod, Larisa;
Semenkovich, Clay F;
Zayed, Mohamed A

Publication type:

Article

Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation.

Published in:

JAFIB: Journal of Atrial Fibrillation, 2021, v. 14, n. 2, p. 1, doi. 10.4022/jafib.20200502

By:

Haloot, Justin;
Krokar, Lucijana;
Badin, Auroa

Publication type:

Article

Sodium‐Glucose Cotransporter‐2 Inhibitor Suppresses Endoplasmic Reticulum Stress and Oxidative Stress in Diabetic Nephropathy Through Nrf2 Signaling: A Clinical and Experimental Study.

Published in:

Journal of Clinical Pharmacology, 2024, v. 64, n. 10, p. 1193, doi. 10.1002/jcph.2465

By:

Prasad, Murali Krishna;
Victor, Paul S.;
Ganesh, Goutham V.;
Juttada, Udayama;
Kumpatla, Satyavani;
Viswanathan, Vijay;
Ramkumar, Kunka Mohanram

Publication type:

Article

Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.

Published in:

Cellular & Molecular Neurobiology, 2023, v. 43, n. 2, p. 879, doi. 10.1007/s10571-022-01221-8

By:

Shoda, Kenji;
Tsuji, Shohei;
Nakamura, Shinsuke;
Egashira, Yusuke;
Enomoto, Yukiko;
Nakayama, Noriyuki;
Shimazawa, Masamitsu;
Iwama, Toru;
Hara, Hideaki

Publication type:

Article

Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.

Published in:

JGIM: Journal of General Internal Medicine, 2022, v. 37, n. 14, p. 3562, doi. 10.1007/s11606-021-07331-1

By:

Luo, Jing;
Feldman, Robert;
Rothenberger, Scott;
Korytkowski, Mary;
Fischer, Michael A.;
Gellad, Walid F.

Publication type:

Article